Want to join the conversation?
For 2016, $LH expects the LabCorp Diagnostics revenue to grow 3.5-5.5% over 2015 pro forma revenue of $6.2Bil after the impact from approx. 50 BP of negative currency. For the Covance Drug Development segment, 2016 revenue is expected to grow 2-5% over 2015 pro forma revenue of $2.6Bil, after the impact from approx. 200 BP of negative currency.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?